<DOC>
	<DOCNO>NCT02355158</DOCNO>
	<brief_summary>Study CLO-311 multicenter , open-label , single-arm study ass long-term use Clonidine Gel treatment pain associate PDN . Subjects complete 12-week participation Study CLO-290 Study CLO-310 eligible rollover study receive active study drug open-label manner .</brief_summary>
	<brief_title>A Safety Study Clonidine Hydrochloride Topical Gel , 0.1 % Treatment Painful Diabetic Neuropathy</brief_title>
	<detailed_description>Study CLO-311 multicenter , open-label , single-arm study ass long-term use Clonidine Gel treatment pain associate PDN . Subjects complete 12-week participation Study CLO-290 Study CLO-310 eligible rollover study receive active study drug open-label manner . All eligible subject receive Clonidine Gel regardless blind treatment receive previous double-blind study ( Clonidine Gel Placebo Gel ) . Study drug apply topically TID foot 12 month Open-Label Treatment Phase . Approximately 400 adult subject PDN estimate enroll study .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>The subject provide write informed consent . The subject Type 1 Type 2 diabetes mellitus glycemic control optimize diet therapy , oral antihyperglycemic agent and/or insulin . The subject must male nonpregnant , nonlactating female . Females must practice acceptable method birth control , surgically sterile postmenopausal ( amenorrhea â‰¥12 month ) . Nonpregnancy confirm ( applicable ) pregnancy test conduct Entry Visit . Doublebarrier method , hormonal contraceptive , abstinence acceptable birth control method study . The subject complete 12week participation accord protocol previously conduct doubleblind study , CLO290 . The subject medically stable endofstudy visit ( Day 85 ) Study CLO290 , opinion Investigator , otherwise good general health base physical examination , ECG , laboratory evaluation . Subject capability apply topical gel foot TID . A caregiver , train study staff apply study medication , would suitable alternative selfapplication treatment . The subject use implanted medical device ( e.g. , spinal cord stimulator , intrathecal pump , peripheral nerve stimulator ) treatment pain . The subject clinically hypotensive rest diastolic blood pressure &lt; 60 mmHg systolic blood pressure &lt; 90 mmHg . The subject recent history ( within past 3 month ) current symptom orthostatic hypotension sudden fall blood pressure stand accompanied dizziness lightheadedness . The subject significant unstable medical psychiatric condition , opinion Investigator , would interfere his/her ability participate study . The subject history substance abuse disorder define DSMIVTR within past 6 month , current evidence substance abuse disorder , receive medicinal treatment drug abuse . The subject symptomatic severe coronary insufficiency , clinically significant cardiac conduction disturbance , myocardial infarction ( within last 6 month ) , cerebrovascular disease , chronic obstructive pulmonary disease ( COPD ) require oxygen therapy . The subject likely noncompliant unreliable provide rating judge Investigator . The subject evidence clinically significant peripheral vascular disease evidence history intermittent claudication evidence vascular ulcer , include venous stasis ulcer . The subject currently take take clonidine form Clonidine Gel study drug ( i.e. , oral , transdermal patch ) past 4 month . The subject develop hypersensitivity intolerance clonidine . The subject currently receive nonoral treatment could affect neuropathic pain . Subject history malignancy within past 5 year exception successfully treat nonmetastatic basal cell squamous cell carcinoma skin and/or localize carcinoma situ cervix . The subject clinical evidence pedal edema venous stasis disease associate significant skin change physical examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>pain</keyword>
	<keyword>diabetic neuropathy</keyword>
	<keyword>pain foot</keyword>
</DOC>